Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...

immune cells that are thought to promote tumor development and metastasis. The researchers will study hedgehog ... About LUNGevity Foundation LUNGevity, the nation's leading lung cancer organization, ...

Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

At the April Sampson Cancer Center on Monday, Tom Uhlman shared his story as part of the Shine a Light on Lung Cancer ...

Some brain tumours can develop from the spread (metastasis) of cancers from other parts of the body. This occurs more ...

In the study, 34 patients with stage 4 metastatic pancreatic cancer were randomized to receive ... A third phase 2 trial in ...

Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy ...